trending Market Intelligence /marketintelligence/en/news-insights/trending/t5kvbu1fccv0kspop-ojrg2 content esgSubNav
In This List

Capricor drug receives US FDA regenerative medicine advanced therapy designation

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Capricor drug receives US FDA regenerative medicine advanced therapy designation

Capricor Therapeutics Inc.'s Duchenne muscular dystrophy treatment, CAP-1002, received the U.S. Food and Drug Administration's regenerative medicine advanced therapy designation.

The designation will expedite development of the drug, which has also received the FDA's orphan drug and rare pediatric disease designations in the past.

Duchenne muscular dystrophy is a genetic disorder characterized by progressive muscle degeneration and weakness, which could lead to death.